Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Vascular Biology

Oligoclonal T Cell Expansions in Atherosclerotic Lesions of Apolipoprotein E–Deficient Mice

Gabrielle Paulsson, Xinghua Zhou, Elisabeth Törnquist, Göran K. Hansson
Download PDF
https://doi.org/10.1161/01.ATV.20.1.10
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:10-17
Originally published January 1, 2000
Gabrielle Paulsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinghua Zhou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Törnquist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Göran K. Hansson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract—T cells are present in atherosclerotic lesions at all stages of development. They exhibit activation markers and are particularly prominent at sites of plaque rupture. This suggests that T-cell–mediated immune responses are involved in the pathogenesis of atherosclerosis. Antigen-specific T cells reactive with oxidized lipoproteins and heat shock proteins have been isolated from plaques, indicating that local activation and clonal expansion might occur. To analyze different stages of atherosclerosis, we have used a murine model. Targeted deletion of the apolipoprotein E gene results in severe hypercholesterolemia and spontaneous atherosclerosis, with lesions containing large numbers of T cells and macrophages. We have analyzed mRNA for T-cell antigen receptors (TCRs) from aortic fatty streaks, early fibrofatty plaques, and advanced fibrofatty plaques of such mice. Polymerase chain reaction amplification of complementarity-determining region 3 (CDR3 region) of TCRs was followed by spectratyping of fragment lengths. This analysis detected all types of variable (V) segments with a gaussian distribution of CDR3 in lymph nodes. In contrast, a restricted heterogeneity was found in atherosclerotic lesions, with expansion of a limited set of Vβ and Vα segments and a monotypic or oligotypic CDR3 spectrum in each lesion. Vβ6 was expressed in all lesions; Vβ5.2, Vβ16, Vα34s, and Vα9, in the majority of lesions; and Vβ6, Vβ5.2, and Vα34S, in lesions at all 3 stages of development. The strongly skewed pattern of the CDR3 region in the TCR is indicative of oligoclonal expansions of T cells and suggests the occurrence of antigen-driven T-cell proliferation in atherosclerosis.

  • atherosclerosis
  • antigen receptors
  • rearrangement
  • T-cell antigen receptors
  • hypercholesterolemia
  • Received May 5, 1999.
  • Accepted June 10, 1999.

Immune mechanisms play an important role in atherosclerosis.1 2 3 4 Monocytes and T cells enter lesions at a very early stage; this process is governed by adhesion molecules and chemokines induced in hypercholesterolemia. The first stage of atherosclerosis, the fatty streak lesion, is largely composed of fat-filled macrophages together with some T cells. Transformation of this lesion into a true fibrofatty atherosclerotic plaque is associated with smooth muscle immigration and the formation of a fibrous cap around the macrophage core. In advanced lesions, activated T cells and macrophages are also important components that secrete cytokines, such as interferon-γ, interleukin-2, tumor necrosis factor-α, and interleukin-1, all of which have been shown to modulate gene expression in vascular endothelial and smooth muscle cells.2 4 5 Finally, inflammatory activation in the advanced plaque leads to metalloproteinase secretion, collagenolytic activity, plaque rupture, thrombosis, arterial occlusion, and infarction.6 This clinical event is associated with the release of inflammatory acute-phase reactants such as interleukin-6 and C-reactive protein (CRP) into the circulation and also with increased levels of circulating activated T cells7 8

The presence of activated T cells suggests that specific immune responses may occur in the plaque. Several candidate antigens have been detected in human and experimental plaques, including oxidized LDL, heat shock proteins, and microbial antigens, such as Chlamydia pneumoniae proteins.9 10 11 In fact, a substantial proportion of CD4+ T cells isolated from human plaques recognize oxidized LDL as an HLA-DR restricted antigen.12 This leads to cell division as well as cytokine secretion, and one would therefore expect to find clonal expansions of antigen-specific CD4+ T cells in plaques. However, this was not confirmed in previous studies of advanced human plaques with the techniques of limited resolving capacity that were available at that time.13 14

An inflammatory process will recruit T cells irrespective of their immunologic specificity; therefore, a chronic inflammatory lesion usually contains a heterogeneous T-cell population. This does not rule out the possibility that chronic lesions contain detectable clonal expansions of T cells at different stages of development. To address this issue, we have analyzed T-cell antigen receptor (TCR) mRNA in atherosclerotic lesions at different stages of disease development. Our data, which used high-resolution analysis of the antigen-binding regions, show the TCR usage to be highly restricted and strongly skewed in both fatty streaks and fibrofatty plaques of apoE-knockout (apoE-KO) mice. This is indicative of oligoclonal expansions of T cells and suggests the occurrence of antigen-driven T-cell proliferation in atherosclerosis.

Methods

Animals

The mice used in the present study were the progeny of apoE-KO animals that were initially created by homologous recombination in embryonic stem cells15 and backcrossed to the C57BL/6 strain for 6 generations. Male mice were weaned at 4 weeks and put on cholesterol-containing diets at 8 weeks of age. One group of mice were fed a “western” diet containing 0.15% cholesterol, and the other mice received a high-cholesterol diet with 1.25% cholesterol and 0.5% cholic acid. Diets are described in detail in Reference 33 . These 2 types of dietary treatment result in serum cholesterol levels of 15 to 20 mmol/L (western diet) and 40 to 50 mmol/L (high-cholesterol diet), respectively.16 Diet and water were provided ad libitum. All experiments were approved by the regional ethical committee for animal welfare.

Time Schedule and Sample Collection

Groups of 3 or 4 mice were killed after 10 or 18 weeks of diet treatment by exsanguination under carbon dioxide anesthesia. After PBS perfusion, both lymph nodes and atherosclerotic lesions from the proximal aorta were carefully dissected out and snap-frozen in liquid nitrogen. Segments of aorta were snap-frozen in OCT compound for cryosectioning.

Immunohistochemistry

Cryosections were processed for immunohistochemistry as previously described3 16 with minor modifications. Briefly, rat anti-mouse CD4 and CD8 (PharMingen) were applied to acetone-fixed cryosections. After a washing step, biotinylated goat anti-rat IgG(H+L) (Dakopatts) was applied, followed by avidin DH/biotinylated peroxidase complex (Vector Laboratory). Controls were stained with irrelevant monoclonal antibodies or without primary antibodies. Sections were counterstained with hematoxylin.

mRNA and cDNA Preparation

After a brief perfusion with PBS, the heart and proximal aorta were dissected out from apoE-KO mice (for treatment, see above) and placed in ice-cold PBS. The atherosclerotic lesions were isolated within 1 hour in under a microscope and frozen immediately into liquid nitrogen. Samples from each mouse (m2 to m7 and m11 to m13) were kept individually (high-cholesterol diet for 10 and 18 weeks, western diet for 18 weeks) except samples 8 to 10 (western diet for 10 weeks), to which lesions from 3 mice were pooled because of the small size of the lesions (Table 1⇓). Aortic lesions and lymph nodes were homogenized individually in a Dismembrator (B. Braun Melsungen AG) while they were still frozen. Lysis buffer (Dynal) was added to the homogenate, mRNA was isolated on oligo-dT–conjugated magnetic beads (Dynabeads, Dynal), and single-stranded cDNA synthesis was performed by using Superscript II (Life Technologies) and random pdN6 primers (Pharmacia) in the presence of Rnasin (Promega).

View this table:
  • View inline
  • View popup
Table 1.

Plaque Samples From Aortic Root of apoE-KO Mice Used in Spectratyping RT-PCR Analysis

PCR Reactions

cDNA, which was analyzed from each sample individually (Table 1⇑), was amplified by polymerase chain reaction (PCR) in a master mix containing 10 mmol/L Tris-HCl, 50 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L dNTP, and 0.2 U/mL Taq polymerase (Life Technologies).17 For amplification of 19 TCR α chain cDNA, a set of 19 Vα primers was used together with 1 Cα primer that had been tagged with FAM fluorochrome (Genset). Similarly, 24 Vβ primers were used with 1 fluorescent Cβ primer to amplify the TCR Vβ chain cDNA. Final concentration of primers was 0.2 μmol/L each. All primers are listed in Table 2⇓. Primer sequences for Vα, Vβ, Cα, and Cβ were used in the reverse transcriptase (RT)-PCR reaction. All sequences were taken from References 1717 to 32. Each reaction was performed in a separate tube; ie, each PCR tube contained one of the alternative V primers together with the C primer. The first PCR cycle started with 2.5 minutes in a hot block at 95°C and then at 56°C (40 seconds) and 72°C (60 seconds). The ensuing 34 cycles consisted of 94°C (40 seconds), 56°C (40 seconds), and 72°C (60 seconds) in a Tetrad (MJ Research). PCR products were analyzed on a high-resolving polyacrylamide gel electrophoresis system in an ABI model 377 automatic DNA sequencer (Perkin-Elmer). Data were analyzed with the Genotyper 2.0 software program.

View this table:
  • View inline
  • View popup
Table 2.

PCR Primers for TCR α and β Chains

Results

ApoE-KO mice were divided into 2 groups that were either fed a high-cholesterol diet with 1.25% cholesterol or a western diet containing 0.15% cholesterol. This leads to different progression rates: whereas mice fed a western diet for 10 weeks exhibited fatty streaks, those fed the high-cholesterol diet for the same length of time had developed fibrofatty plaques.33 34 The latter type of lesions were observed in mice maintained on the western diet for 18 weeks, whereas mice fed the high-cholesterol diet for 18 weeks exhibited large, advanced fibrofatty plaques (Figure 1⇓). The different diet treatments result in different immune effector mechanisms,16 and the present design permitted us to evaluate whether the immune detector mechanisms also varied depending on serum cholesterol levels or disease progression rate.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

CD4+ T cells in fibrofatty plaques from aortic root of apoE−/− mice. Immunohistochemical staining of lesions from mice fed the high-cholesterol diet for 10 weeks (EH10) or 18 weeks (EH18) as well as mice fed the western diet for 18 weeks (EW18) is shown. The frames in the top panels are shown in the bottom panels at higher magnification. Magnification ×50 (top panels) and ×200 (bottom panels). The arrows point at sites in lesions that stain positive for CD4+ T cells. A calcification is marked with an asterisk.

An immunohistochemical analysis of lesions from the different groups of mice confirmed the abundance of CD4+ T cells in all types of lesions (Figure 1⇑).

Atherosclerotic lesions were microdissected from the aortic root of each mouse. The sample from each mouse (Table 1⇑) was treated individually (except samples 8 to 10; see Methods). The mRNA was isolated individually and used for RT-PCR analysis (see below). For comparison, mRNA from lymph node tissue was also analyzed. The TCR V region repertoire was analyzed by using 5′ primers specific for the different V domains in combination with a common 3′ primer from the C domain. This analysis provides information about the usage of different V domains by T cells in lesions. However, immune specificity is determined not only by V domain usage but also by nucleotide transferase activity associated with recombination events during T-cell differentiation. This activity adds or removes nucleotides at the various Vα-Jα, Vβ-Dβ, and Dβ-Jβ junctions in the maturing TCR genes and results in variations in the length of the mature TCRα and TCRβ genes. Together, V domain usage and junctional variability determine the conformation of the complementarity-determining region 3 (CDR3 region) of the TCR, which in turn determines the binding specificity of the antigen receptor.35 36 To assess junctional diversity as well as V domain usage, PCR was followed by fragment length analysis on high-resolution polyacrylamide gels in a DNA sequencer. The spectrum of size differences across the CDR3 region is known as the spectratype. Because the relative intensity of a given size peak is proportional to the amount of mRNA molecules in the starting material, an increase in height and area of a particular peak signals expansion of T-cell clones.17

When Vα and Vβ profiles were run on lymph nodes, each TCR type (except Vα9 and Vβ12) showed a gaussian distribution (Figures 2⇓ and 3⇓). Each peak within one V region profile differed by 3 bp, corresponding to peptide differences of 1 amino acid. Five to 7 different peaks were found for each TCR fragment, corresponding to a variation in length of 5 to 7 amino acids within the CDR3 region.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Spectratype profiles of the CDR3 length diversity in the Vα chain mRNA of TCR in atherosclerotic plaques. mRNA was extracted from plaques or lymph nodes (control tissue), and RT-PCR analysis of the CDR3 region in the TCR was performed as described in Methods. The PCR reaction was run with a fluorescently labeled common C-region primer and V-region–specific primers for each Vα. PCR products were analyzed on high-resolving PAGE in an automatic sequencer. The y axis shows fluorescence intensity; the x axis, CDR3 size. The boxed numbers show the length in base pairs of the PCR products in the corresponding peak. Each row contains all PCR products derived from one sample with use of the complete panel of Vα primers. All rows show the analysis from individual apoE−/− mice (m2, m3, etc), except for m8 to 10, for which samples from 3 mice were pooled. Sample number (m2 to m13), time on diet in weeks (w), and type of diet (either high-cholesterol diet [HCD] or western diet [WD]) are indicated. Top row, Lymph nodes of apoE−/− mice fed HCD for 10 weeks show gaussian distribution of CDR3 profiles corresponding to a polyclonal T-cell population. Subsequent rows, Plaques from apoE−/− mice have strongly skewed repertoires for the Vα TCR, indicating monoclonal or oligoclonal T-cell populations.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Spectratype profiles of the CDR3 length diversity in the Vβ chain of the TCR in T cells infiltrating the atherosclerotic plaque. The analysis was performed as in Figure 2⇑ and on the same samples; eg, sample m2 is from the same mouse in both Vα and Vβ analyses. Top row, Lymph nodes of apoE−/− mice fed HCD for 10 weeks show gaussian distribution of CDR3 profiles corresponding to a polyclonal T-cell population. Subsequent rows, Plaques of apoE−/− mice exhibit strongly skewed repertoires for the Vβ TCR, indicating monoclonal or oligoclonal T-cell population.

The TCR analysis of plaque tissue gave a totally different result, as shown in Figures 2⇑ and 3⇑ and in Table 3⇓. First, only a limited set of V domains was represented in each of the 10 samples. The number of V domains expressed in each aorta varied between 1 and 8, with an average of 5.2 Vα and 5.6 Vβ domains. Second, the detected TCR fragments exhibited strongly skewed profiles and never showed the gaussian distribution found in lymph nodes. In several samples, only one peak was visible, implying a monotypic expansion of T cells (eg, Figure 3⇑, row m2, Vβ6).

View this table:
  • View inline
  • View popup
Table 3.

Frequency of V Regions Found in TCR-Infiltrating Plaque

Vβ6 was expressed as a dominant peak in all aortic samples (Figure 3⇑ and Table 3⇑). In 4 of them, a single peak of TCR Vβ6 was observed, indicating a monoclonal T-cell population within these plaques (eg, Figure 3⇑, rows m2 and m7). In the 6 remaining samples, 2 expanded peaks were identified (eg, Figure 3⇑, rows m5 and m6). The second most common Vβ domains, Vβ5.2 and Vβ16, were expressed in 5 of the 10 samples.

In the Vα analysis, the most frequent V domain was 34S, which was found in 9 of 10 samples (Table 3⇑). As for Vβ6, the profile was skewed, and one peak was dominant. The second most common Vα domain expressed was Vα9, which was also present as a single peak. However, it occurred as a single peak also in the lymph nodes. This transcript is probably derived from a rearranged pseudogene.22

When comparing the mice fed a western diet with those maintained on the high-cholesterol diet, we found no differences in TCR profiles. In contrast, the stage of lesions appeared to influence the TCR patterns: more advanced lesions exhibited a more restricted TCR heterogeneity than did earlier stages of disease. This was particularly evident for Vβ domains; compare samples m2 to m4 in Figure 3⇑, which represent advanced fibrofatty lesions, with samples m11 to m13, which are derived from early fibrofatty plaques.

Discussion

A cellular immune response to a specific antigen induces proliferation of antigen-specific T cells, and this leads to expansion of T-cell clones carrying one unique TCR. Because T cells are important components of the atherosclerotic lesion at all stages and may recognize antigens present in the lesions, it is important to clarify whether clonal expansions of antigen-specific T cells occur in atherosclerosis.1 3 Previous studies of complicated human carotid lesions have failed to provide evidence for such expansions,13 14 but the situation may be entirely different in other phases of atherosclerosis. The development of murine models of the disease permits a dissection of all the phases of the disease with the use of clonotypic T-cell markers. The use of the recently developed spectratyping RT-PCR technique reveals the Vα and Vβ gene usage together with the unique length of the CDR3 region in each T cell and serves as a clonotypic indicator.17 Because the mouse models have defined genotypes and not the same degree of complexity in the major histocompatibility complex (MHC) gene cluster as the human patients show in their HLA, this will be reflected in the TCR usage. In particular, the V domain usage will be less diverse, because all the mice in the present study carry the same MHC genes. Finally, the sensitivity of spectratyping allows an analysis of the antigen-binding domain of the TCR at a level that was not possible before when only Southern blot analysis14 or standard PCR13 was available.

With this approach of spectratyping RT-PCR of the TCR, we now demonstrate that the T-cell population of atherosclerotic lesions is highly skewed compared with the gaussian distribution found in lymph nodes. Not only is the representation of V domains much more limited in the lesions, but the CDR3 variability is also much more restricted. Interestingly, TCR heterogeneity was more reduced in the more mature plaques compared with earlier ones. This could imply that a heterogeneous population of T cells is initially recruited to the forming lesion by antigenically nonspecific mechanisms, followed by a selective expansion of T cells carrying specific reactivity to local antigens. The comparison with very advanced human lesions suggests that such a selective expansion is followed by extended chronic inflammation, leading to adhesion and immigration of heterogeneous T cells and a dilution of the specific population. This possibility should be tested when the precise specificities of the TCR represented in the human lesions are known.

One TCR V domain was represented in all lesions: Vβ6. Only 1 or 2 Vβ6 peaks were found in most samples, and the dominant peaks were 179 to 182 bp and thus differed by only 1 codon. It seems likely that this expansion of TCR Vβ6 was caused by proliferation of antigen-specific T cells carrying this TCR. This expansion could theoretically arise either from an expanded population of activated Vβ6+ T cells in the blood or by local proliferation of Vβ6+ T cells in the plaque. Because no expansion of Vβ6+ T cells was observed in lymph nodes, it is less probable that a systemically expanded Vβ6 population was recruited to the lesion. Instead, the most likely explanation for the selective expansion of Vβ6 mRNA in lesions is that Vβ6+ T cells undergo local clonal proliferation in the lesion itself. This, in turn, suggests that plaque components are presented as antigens to local T cells. We have previously shown that CD4+ T cells of human lesions recognize oxidized LDL, and we have recently observed that murine T-cell hybridomas reactive with oxidation-induced LDL epitopes express Vβ6 (A. Nicoletti, G. Paulsson, G.K. Hansson, unpublished observation, 1999). Together, these results suggest that TCR Vβ6 is used in the recognition of oxidized LDL in atherosclerotic lesions, leading to clonal expansion of CD4+ T cells carrying this type of TCR.

In contrast to the dominance of Vβ6, no single Vα domain was expressed in any lesion sample. Although TCR Vα34S was present in 9 of 10 lesion samples, it was missing in 1 of 3 early fibrofatty plaques of the apoE-KO mice fed a western diet (Figure 2⇑, m7). Therefore, Vα expression was more heterogeneous than Vβ expression, possibly reflecting a promiscuous usage of Vα domains in the generation of antigen-specific TCR–recognizing plaque antigens. This interpretation is in line with recent observations that each T-cell epitope can be recognized by many different TCRs and that each clonotypic TCR can recognize many different epitopes.37 38

In spite of the relative heterogeneity of Vα expression, the selective expression of T cells carrying Vβ6 suggests that such cells are important in the pathogenesis of atherosclerosis. Autoimmune diseases such as experimental autoimmune encephalomyelitis have been reversed by treatment with monoclonal antibodies specific for the TCR-Vβ type carried by disease-mediating T cells.39 It will now be interesting to determine whether atherosclerosis can also be controlled by such reagents.

Acknowledgments

This study was supported by grants from the Swedish Medical Research Council (project No. 6816), the Heart-Lung Foundation, and the Hedlund, Johnson, Tore Nilsson, Nanna Svartz, King Gustaf V, and Gamla Tjänarinnor funds. E. Törnquist was supported by a fellowship from the National Network for Cardiovascular Research. We thank Ingrid Törnberg for excellent technical assistance.

References

  1. ↵
    Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131–138.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5–15.
    OpenUrlPubMed
  3. ↵
    Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis: CD4+ T cells infiltrate lesions of apo E-deficient mice. Am J Pathol.. 1996;149:359–366.
    OpenUrlPubMed
  4. ↵
    Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol.. 1997;8:301–311.
    OpenUrlPubMed
  5. ↵
    Hansson GK, Stemme V, Yokota T; Remick D, Friedland J, eds. Cytokines and the Cardiovascular System. Philadelphia, Pa: Lippincott-Raven Publishers; 1997:507–517.
  6. ↵
    Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850.
    OpenUrlFREE Full Text
  7. ↵
    Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore R, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94:2373–2380.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Caligiuri G, Liuzzo G, Biasucci LM, Maseri A. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol. 1998;32:1295–1304.
    OpenUrlCrossRefPubMed
  9. ↵
    Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32–40.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Xu Q, Kleindienst R, Waitz W, Dietrich H, Wick G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest.. 1993;91:2693–702.
  11. ↵
    Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841–849.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb.. 1992;12:206–211.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Swanson SJ, Rosenzweig A, Seidman JG, Libby P. Diversity of T-cell antigen receptor V beta gene utilization in advanced human atheroma. Arterioscler Thromb. 1994;14:1210–1214.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Stemme S, Rymo L, Hansson GK. Polyclonal origin of T lymphocytes in human atherosclerotic plaques. Lab Invest. 1991;65:654–660.
    OpenUrlPubMed
  15. ↵
    Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A.. 1992;89:4471–4475.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a Th1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998;101:1717–1725.
    OpenUrlCrossRefPubMed
  17. ↵
    Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A. 1993;90:4319–4323.
    OpenUrlAbstract/FREE Full Text
  18. Patten P, Yokota T, Rothbard J, Chien Y, Arai K, Davis MM. Structure, expression and divergence of T-cell receptor beta-chain variable regions. Nature. 1984;312:40–46.
    OpenUrlCrossRefPubMed
  19. Chien YH, Gascoigne RJ, Kavaler J, Lee NE, Davis MM. Somatic recombination in a murine T-cell receptor gene. Nature. 1984;309:322–326.
    OpenUrlCrossRefPubMed
  20. Chien Y, Becker DM, Lindsten T, Okamura M, Cohen DI, Davis MM. A third type of murine T-cell receptor gene. Nature. 1984;312:31–35.
    OpenUrlCrossRefPubMed
  21. Gascoigne NR, Chien Y, Becker DM, Kavaler J, Davis MM. Genomic organization and sequence of T-cell receptor beta-chain constant- and joining-region genes. Nature. 1984;310:387–391.
    OpenUrlCrossRefPubMed
  22. ↵
    Arden B, Klotz JL, Siu G, Hood LE. Diversity and structure of genes of the alpha family of mouse T-cell antigen receptor. Nature. 1985;316:783–787.
    OpenUrlCrossRefPubMed
  23. Barth RK, Kim BS, Lan NC, Hunkapiller T, Sobieck N, Winoto A, Gershenfeld H, Okada C, Hansburg D, Weissman IL, et al. The murine T-cell receptor uses a limited repertoire of expressed V beta gene segments. Nature. 1985;316:517–523.
    OpenUrlCrossRefPubMed
  24. Behlke MA, Loh DY. Alternative splicing of murine T-cell receptor beta-chain transcripts. Nature. 1986;322:379–382.
    OpenUrlCrossRefPubMed
  25. Behlke MA, Chou HS, Huppi K, Loh DY. Murine T-cell receptor mutants with deletions of beta-chain variable region genes. Proc Natl Acad Sci U S A. 1986;83:767–771.
    OpenUrlAbstract/FREE Full Text
  26. Chou HS, Behlke MA, Godambe SA, Russell JH, Brooks CG, Loh DY. T cell receptor genes in an alloreactive CTL clone: implications for rearrangement and germline diversity of variable gene segments. EMBO J. 1986;5:2149–2155.
    OpenUrlPubMed
  27. Tillinghast JP, Behlke MA, Loh DY. Structure and diversity of the human T-cell receptor beta-chain variable region genes. Science. 1986;233:879–883.
    OpenUrlAbstract/FREE Full Text
  28. Chou HS, Nelson CA, Godambe SA, Chaplin DD, Loh DY. Germline organization of the murine T cell receptor beta-chain genes. Science. 1987;238:545–548.
    OpenUrlAbstract/FREE Full Text
  29. Chou HS, Anderson SJ, Louie MC, Godambe SA, Pozzi MR, Behlke MA, Huppi K, Loh DY. Tandem linkage and unusual RNA splicing of the T-cell receptor beta-chain variable-region genes. Proc Natl Acad Sci U S A. 1987;84:1992–1996.
    OpenUrlAbstract/FREE Full Text
  30. Kappler JW, Wade T, White J, Kushnir E, Blackman M, Bill J, Roehm N, Marrack P. A T cell receptor V beta segment that imparts reactivity to a class II major histocompatibility complex product. Cell. 1987;49:263–271.
    OpenUrlCrossRefPubMed
  31. Koide Y, Kaidoh T, Yanagawa T, Yoshida TO. A comparative study on T cell receptor V beta gene usages: spleen cells from the non-obese diabetic (NOD) mouse and its non-diabetic sister strain, the ILI mouse, and infiltrating T cells into pancreata of NOD mice. Microbiol Immunol. 1993;37:653–659.
    OpenUrlPubMed
  32. Casanova JL, Romero P, Widmann C, Kourilsky P, Maryanski JL. T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J Exp Med. 1991;174:1371–1383.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E: evaluation of lesional development and progression [published erratum appears in Arterioscler Thromb. 1994;14:839]. Arterioscler Thromb. 1994;14:141–147.
    OpenUrl
  34. ↵
    Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133–140.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Chothia C, Boswell DR, Lesk AM. The outline structure of the T-cell alpha beta receptor. EMBO J. 1988;7:3745–3755.
    OpenUrlPubMed
  36. ↵
    Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition [published erratum appears in Nature. 1988;20;335:744]. Nature.. 1988;334:395–402.
    OpenUrlCrossRefPubMed
  37. ↵
    Breiteneder H, Friedl HR, Ebner C, Schenk S, Fischer G, Kraft D, Scheiner O. Sequence comparisons of the CDR3 hyper-variable loops of human T cell receptors specific for three major T cell epitopes of the birch pollen allergen Bet v 1. Mol Immunol.. 1996;33:1039–1048.
    OpenUrlCrossRefPubMed
  38. ↵
    Gapin L, Fukui Y, Kanellopoulos J, Sano T, Casrouge A, Malier V, Beaudoing E, Gautheret D, Claverie JM, Sasazuki T, Kourilsky P. Quantitative analysis of the T cell repertoire selected by a single peptide-major histocompatibility complex. J Exp Med. 1998;187:1871–1883.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988;54:263–273.
    OpenUrlCrossRefPubMed
  40. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272:685–688.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
January 2000, Volume 20, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Oligoclonal T Cell Expansions in Atherosclerotic Lesions of Apolipoprotein E–Deficient Mice
    Gabrielle Paulsson, Xinghua Zhou, Elisabeth Törnquist and Göran K. Hansson
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:10-17, originally published January 1, 2000
    https://doi.org/10.1161/01.ATV.20.1.10

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Oligoclonal T Cell Expansions in Atherosclerotic Lesions of Apolipoprotein E–Deficient Mice
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Oligoclonal T Cell Expansions in Atherosclerotic Lesions of Apolipoprotein E–Deficient Mice
    Gabrielle Paulsson, Xinghua Zhou, Elisabeth Törnquist and Göran K. Hansson
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:10-17, originally published January 1, 2000
    https://doi.org/10.1161/01.ATV.20.1.10
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured